Evidence map›Paper›PMID 30978018›Full record

ArticleThe Journal of organic chemistry2019

Synthesis of Terminal Ribose Analogues of Adenosine 5'-Diphosphate Ribose as Probes for the Transient Receptor Potential Cation Channel TRPM2.

Ondřej Baszczyňski, Joanna M Watt, Monika D Rozewitz, Andreas H Guse, Ralf Fliegert, Barry V L Potter

Open access · hybridAbstract read
In one paragraph

Article in The Journal of organic chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. [Advances in the development of transient receptor potential melastatin 2 channel inhibitors].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2025
    Review
  4. Roles of NADMolecules (Basel, Switzerland) · 2020
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Ondřej BaszczyňskiWolfson Laboratory of Medicinal Chemistry, Department of Pharmacy and Pharmacology , University of Bath , Bath BA2 7AY , U.K.
Joanna M WattMedicinal Chemistry & Drug Discovery, Department of Pharmacology , University of Oxford , Mansfield Road , Oxford OX1 3QT , U.K.
Monika D RozewitzThe Calcium Signalling Group, Department of Biochemistry and Molecular Cell Biology , University Medical Center Hamburg-Eppendorf , Martinistrasse 52 , 20246 Hamburg , Germany.
Andreas H GuseThe Calcium Signalling Group, Department of Biochemistry and Molecular Cell Biology , University Medical Center Hamburg-Eppendorf , Martinistrasse 52 , 20246 Hamburg , Germany.
Ralf FliegertThe Calcium Signalling Group, Department of Biochemistry and Molecular Cell Biology , University Medical Center Hamburg-Eppendorf , Martinistrasse 52 , 20246 Hamburg , Germany.
Barry V L PotterMedicinal Chemistry & Drug Discovery, Department of Pharmacology , University of Oxford , Mansfield Road , Oxford OX1 3QT , U.K.ORCID 0000-0003-3255-9135
Universität Hamburg · DEMansfield University · USUniversity of Bath · GB

Funding

Wellcome Trust 101010
6 · The paper itself

Abstract

TRPM2 (transient receptor potential cation channel, subfamily M, member 2) is a nonselective cation channel involved in the response to oxidative stress and in inflammation. Its role in autoimmune and neurodegenerative diseases makes it an attractive pharmacological target. Binding of the nucleotide adenosine 5'-diphosphate ribose (ADPR) to the cytosolic NUDT9 homology (NUDT9 H) domain activates the channel. A detailed understanding of how ADPR interacts with the TRPM2 ligand binding domain is lacking, hampering the rational design of modulators, but the terminal ribose of ADPR is known to be essential for activation. To study its role in more detail, we designed synthetic routes to novel analogues of ADPR and 2'-deoxy-ADPR that were modified only by removal of a single hydroxyl group from the terminal ribose. The ADPR analogues were obtained by coupling nucleoside phosphorimidazolides to deoxysugar phosphates. The corresponding C2″-based analogues proved to be unstable. The C1″- and C3″-ADPR analogues were evaluated electrophysiologically by patch-clamp in TRPM2-expressing HEK293 cells. In addition, a compound with all hydroxyl groups of the terminal ribose blocked as its 1″-β- O-methyl-2″,3″- O-isopropylidene derivative was evaluated. Removal of either C1″ or C3″ hydroxyl groups from ADPR resulted in loss of agonist activity. Both these modifications and blocking all three hydroxyl groups resulted in TRPM2 antagonists. Our results demonstrate the critical role of these hydroxyl groups in channel activation.

Indexed as

Adenosine Diphosphate RiboseChemistry Techniques, SyntheticHEK293 CellsHumansModels, MolecularMolecular ProbesProtein ConformationTRPM Cation ChannelsAdenosine Diphosphate RiboseMolecular ProbesTRPM2 protein, humanTRPM Cation Channels

Identifiers

PMID30978018
PMCPMC6528165
OpenAlexW2938632292

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.